EyePoint Pharmaceuticals (formerly pSivida) is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon. The injectable, sustained release micro-insert ILUVIEN for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., and utilizes the third generation of the Durasert technology. The Company's two FDA-approved products, Retisert and Vitrasert, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.